Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans

Brown, Randi, Lissemore, Jennifer, Shinozuka, Kenneth, Coetzee, John, Faerman, Afik, Olash, Clayton, Geoly, Andrew, Buchanan, Derrick, Cherian, Kirsten, Chaiken, Anna, Shamma, Ahmed, Sridhar, Malvika, Hunegnaw, Saron, Johnson, Noriah, Rolle, Camarin, Adamson, Maheen, Williams, Nolan · 2025 · Journal of Affective Disorders

AI-extracted · unverified · confirm at source

n=30 veterans with TBI; higher MEQ30 predicted larger PTSD reductions at immediate (B=-5.89, p<.001) and 1-month (B=-4.45, p=.007) follow-up. Mystical experience also predicted decreased peak alpha frequency at 1 month. MISTIC protocol.

Dosing: Test dose 2–3 mg/kg, total ≤14 mg/kg oral (ibogaine HCl, 98% pure); 1g IV MgSO₄ pre-dosing (oral)

Sample size: 30

Safety data present: ELECTROLYTE

Contraindications: History of psychotic symptoms, Neurological disorder (excluding TBI sequelae), Clinical abnormalities affecting participant safety or study integrity, Risk for suicidal behaviour during study period, Concurrent participation in another clinical trial, Contraindication to MRI